Femasys Inc. (NASDAQ:FEMY) Short Interest Update

Femasys Inc. (NASDAQ:FEMYGet Rating) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 131,700 shares, a decline of 51.1% from the March 31st total of 269,200 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 206,000 shares, the short-interest ratio is presently 0.6 days.

Several institutional investors and hedge funds have recently made changes to their positions in FEMY. Millennium Management LLC bought a new position in shares of Femasys in the 2nd quarter valued at $109,000. BlackRock Inc. acquired a new stake in Femasys in the third quarter valued at $40,000. Tri Locum Partners LP increased its holdings in Femasys by 1.0% in the third quarter. Tri Locum Partners LP now owns 190,600 shares of the company’s stock valued at $1,313,000 after purchasing an additional 1,847 shares during the period. Clear Creek Financial Management LLC increased its holdings in Femasys by 190.2% in the fourth quarter. Clear Creek Financial Management LLC now owns 68,276 shares of the company’s stock valued at $266,000 after purchasing an additional 44,752 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new stake in Femasys in the fourth quarter valued at $514,000. Institutional investors own 6.27% of the company’s stock.

Several equities research analysts recently issued reports on FEMY shares. Chardan Capital cut their price target on Femasys from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 25th. Zacks Investment Research upgraded Femasys from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Friday, December 31st. Finally, HC Wainwright assumed coverage on Femasys in a research note on Thursday, March 24th. They set a “buy” rating and a $8.00 target price for the company.

Shares of FEMY opened at $1.63 on Friday. Femasys has a 52 week low of $1.42 and a 52 week high of $13.75. The company has a current ratio of 15.15, a quick ratio of 15.03 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $2.08 and a 200-day moving average of $3.76.

Femasys (NASDAQ:FEMYGet Rating) last announced its quarterly earnings results on Thursday, March 24th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $0.25 million during the quarter. Sell-side analysts predict that Femasys will post -0.93 earnings per share for the current fiscal year.

Femasys Company Profile (Get Rating)

Femasys Inc, a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.

Recommended Stories

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.